Loading…
Hosted by Oncololgy News Central · EN · 100 episodes
Established thought leaders with verified media credentials.
Peer-Spectives is a podcast series that is moderated by Robert Figlin, MD, and features various oncology thought-leaders covering the latest clinical developments in a wide range of tumor types.
Oncololgy News Central hosts Oncology News Central Peer-Spectives, a science show with 100 episodes published.
The prospective randomized NHS-Galleri multicancer early detection trial didn’t meet its primary endpoint, but it did uncover a lot more early-stage cancers than predicted. Eric Klein, MD, and Robert Figlin, MD, talk abo
Data presented at the 2026 American Society of Clinical Oncology Annual Meeting add to the “ever-shifting and chaotic space” that is CLL care, says Matthew Lunning, DO. He discusses how new findings are affecting practic
New treatments for patients with microsatellite instability–high colorectal cancer are drastically changing outcomes. Nicholas James Hornstein, MD, PhD, discusses recent advances and key findings from the 2026 American S
In the wake of recent key data about ESR1-mutated metastatic breast cancer, treatment decisions have become more complicated. “In current clinical practice, this is not a straightforward decision,” Marla Lipsyc-Sharf, MD
“In breast cancer now, all of our treatment for hormone receptor–positive metastatic disease is a bit of a moving target because of new therapies that are available,” explains Hope S. Rugo, MD, division chief of breast m
As the management of patients with ESR1-mutated metastatic breast cancer evolves, various questions have emerged in clinical practice. “It's a complex situation,” explains Hope S. Rugo, MD, division chief of breast medic
How are oncologists currently approaching the care of patients with ESR1-mutated advanced breast cancer in practice? Erin Frances Cobain, MD , associate professor at the University of Michigan Rogel Cancer Center in Ann
Combination regimens improve survival in advanced EGFR-mutated NSCLC, but they also increase toxicity. Jorge Nieva, MD, shares how he talks with patients about potential adverse events. He describes the options available
Tackling central nervous system (CNS) disease in EGFR-mutated non-small cell lung cancer “is a huge problem, both from a quality-of-life perspective for patients and also from a longevity perspective,” explains Sid Devar
With multiple regimens available for advanced EGFRm NSCLC, selecting the best regimen for an individual patient is key. Jorge Nieva, MD, tells host Aakash Desai, MD, MPH, that the question shouldn’t be about who needs mo
Progress in cancer care means that millions of patients are living longer lives, albeit without hope of a cure. What role can oncologists and other physicians play in helping to navigate these uncertain futures? “What is
A recent study found a link between mRNA vaccination and improved cancer immunotherapy response. The preclinical data demonstrated impressive results, leading to big questions. “We believe that [vaccination] actually doe
Survival data from the KEYNOTE-905 trial and insights into the use of circulating tumor DNA to guide treatment decisions from IMvigor011 made big waves in bladder cancer care at the European Society of Medical Oncology A
Options for the treatment of acute myeloid leukemia (AML) are rapidly expanding, says Amir Fathi, MD, associate professor of medicine at Harvard Medical School in Boston and program director of the Center for Leukemia at
The artificial sweetener sucralose may impair the efficacy of cancer immunotherapy, according to a recent study published in Science. Although further research is needed before these findings can be translated into actio
New survival data from the FLAURA2 and MARIPOSA trials represent “a massive advance for our patients” in terms of frontline treatment for EGFR-mutated non-small cell lung cancer says Sandip P. Patel, MD, professor of med
The development of oral selective estrogen receptor degraders (SERDs) represents substantial progress for patients with metastatic breast cancer who have ESR1 mutations. “I’m extremely excited because they’re the most ef
From a “game-changer” in triple-negative disease to broader paradigm shifts and practice changes, the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting was pivotal for breast cancer care, says Sara M. Tola
Results from the phase 3 ATOMIC trial are practice changing for colorectal cancer care and raise broader questions about immunotherapy use in patients with mismatch repair deficiencies across tumor types. Frank A. Sinicr
“An increasingly unrealistic set of performance expectations” is putting a strain on oncologist faculty members, says Clifford Hudis, MD, CEO of the American Society of Clinical Oncology (ASCO). He discussed the mounting
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
To pitch Oncology News Central Peer-Spectives, visit https://peer-spectives.podbean.com for contact information, then craft a tight one-paragraph hook that ties your expertise to a gap in their recent science coverage.
Oncology News Central Peer-Spectives is hosted by Oncololgy News Central. The show is categorised under science and has published 100 episodes.
Oncology News Central Peer-Spectives has published 100 episodes.
Oncology News Central Peer-Spectives regularly covers science. It sits in the science category.
Oncology News Central Peer-Spectives is accessible for guests with genuine science expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
Oncology News Central Peer-Spectives hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of Oncology News Central Peer-Spectives average 13 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates Oncology News Central Peer-Spectives's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 6 days ago.